Stock Analysis

DaisuiLtd Third Quarter 2025 Earnings: EPS: JP¥29.51 (vs JP¥33.51 in 3Q 2024)

TSE:7538
Source: Shutterstock

DaisuiLtd (TSE:7538) Third Quarter 2025 Results

Key Financial Results

  • Revenue: JP¥29.8b (up 1.4% from 3Q 2024).
  • Net income: JP¥400.0m (down 12% from 3Q 2024).
  • Profit margin: 1.3% (down from 1.5% in 3Q 2024). The decrease in margin was driven by higher expenses.
  • EPS: JP¥29.51 (down from JP¥33.51 in 3Q 2024).
earnings-and-revenue-history
TSE:7538 Earnings and Revenue History February 9th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

DaisuiLtd shares are down 3.1% from a week ago.

Risk Analysis

We should say that we've discovered 1 warning sign for DaisuiLtd that you should be aware of before investing here.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About TSE:7538

DaisuiLtd

Engages in the wholesale of marine products in Japan.

Excellent balance sheet second-rate dividend payer.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|36.403% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|25.014999999999997% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|4.1226% overvalued
Jonataninho
Jonataninho
Community Contributor